Duo-Radiant

Duo-Radiant is a clinical-stage biopharmaceutical company specializing in the discovery and development of next-generation radiopharmaceuticals for oncology. The company's core focus is on targeted radioligand therapies (RLT) that utilize both alpha and beta isotopes to treat various solid tumors. Its lead candidate, DR-101, is a PSMA-targeted radiopharmaceutical currently in Phase 1 clinical trials for the treatment of prostate cancer. Duo-Radiant also has a robust pipeline of early-stage programs targeting Fibroblast Activation Protein (FAP) and other high-value oncology targets. Headquartered in Suzhou, China, the company is backed by prominent life science investors and led by a team with extensive experience in the radiopharmaceutical industry.